Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06676280 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

Study acronym: ASA-3C
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 26 → 32 locationsv9
  2. Trial sites expanded: 1 → 26 locations Eligibility criteria revisedv8 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  3. Eligibility criteria revisedv7 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jul 1, 2025 to Jul 24, 2025v6 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 1, 2025 to Jul 24, 2025
  5. Primary completion date: Apr 28, 2033 to Mar 31, 2035 Start date: Apr 28, 2025 to Jul 1, 2025 · Completion date: Dec 31, 2033 to Dec 31, 2035 · Eligibility criteria expanded, about 58 words · 1 morev5 Show 4 more changesShow less
    • Start date: Apr 28, 2025 to Jul 1, 2025
    • Completion date: Dec 31, 2033 to Dec 31, 2035
    • Eligibility criteria expanded, about 58 words
    • Secondary endpoints: details revised at 5 of 5 entries

    See this version in full on ClinicalTrials.gov ↗

Show 3 earlier versionsHide 3 earlier versions
  1. Eligibility criteria revisedv4 See this version in full on ClinicalTrials.gov ↗
  2. Eligibility criteria expanded, about 23 words Secondary endpoints: 4 to 5 · Study title expanded, about 2 wordsv3 Show 2 more changesShow less
    • Secondary endpoints: 4 to 5
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Interventions: Aspirin (Drug), High-intensity statin (Drug) to Aspirin (Drug), Guideline-directed statin therapy (Drug), High-intensity statin (Drug) Study arms: 2 to 4v2 Show 1 more changeShow less
    • Study arms: 2 to 4
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).
Trial Details
NCT Number NCT06676280
Lead Sponsor Jung-min Ahn
Conditions Cardiovascular Diseases
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov